Agenus to Participate at B Riley Securities’ 2023 Virtual Oncology Conference

Rhea-AI Summary

Agenus (NASDAQ: AGEN), an immuno-oncology firm, announced participation by Chairman and CEO Dr. Garo Armen and Chief Medical Officer Dr. Steven O’Day in a virtual fireside chat at the B Riley Securities’ 2023 Virtual Oncology Conference on January 18th at 11:30 am ET. This event offers insights into Agenus's innovative therapies targeting cancer and infections. Interested participants can register for the webcast at B Riley's website. An archived version will be available later on Agenus's Investor page, providing ongoing updates about the company's developments.

Argus Session date unavailable

+11.39% session move Open Argus

Details

News Market Reaction – AGEN

The recorded move for AGEN in the trading session of this news was +11.39%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LEXINGTON, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO of Agenus, and Dr. Steven O’Day, Chief Medical Officer, will participate in a virtual fireside chat at the B Riley Securities’ 2023 Virtual Oncology Conference on Wednesday, January 18th at 11:30am ET.

Registration for the webcast can be accessed at https://brileyoncology22.sequireevents.com/. Following the webcast, an archived version will be available on the Investors section of the Agenus website at https://investor.agenusbio.com/events-and-presentations.

About Agenus

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

Contact
Agenus Inc.
Zack Armen
Head of Investor Relations
917-362-1370
zack.armen@agenusbio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What details were announced by Agenus on January 10, 2023?

Agenus announced that Dr. Garo Armen and Dr. Steven O’Day will participate in a virtual fireside chat at the B Riley Securities’ 2023 Virtual Oncology Conference on January 18th.

How can I register for the B Riley Securities 2023 Virtual Oncology Conference?

Registration for the conference is available at https://brileyoncology22.sequireevents.com/.

Where can I find the archived version of the Agenus virtual fireside chat?

The archived version will be available on the Investors section of the Agenus website after the event.

What is the main focus of Agenus as a company?

Agenus focuses on developing immuno-oncology therapies that engage the immune system to combat cancer and infections.

Who is participating in the virtual fireside chat for Agenus?

Dr. Garo Armen, Chairman and CEO, and Dr. Steven O’Day, Chief Medical Officer, will participate in the chat.